C2N Diagnostics receives $15M investment to advance its blood test for Alzheimer's disease
The biotechnology startup plans to use its funding to develop a second version of its blood test that aims to help diagnose Alzheimer's disease.
The biotechnology startup plans to use its funding to develop a second version of its blood test that aims to help diagnose Alzheimer's disease.